Literature DB >> 21030213

Kynurenine 3-monooxygenase (KMO) polymorphisms in schizophrenia: an association study.

Maria Holtze, Peter Saetre, Sophie Erhardt, Lilly Schwieler, Thomas Werge, Thomas Hansen, Jimmi Nielsen, Srdjan Djurovic, Ingrid Melle, Ole A Andreassen, Håkan Hall, Lars Terenius, Ingrid Agartz, Göran Engberg, Erik G Jönsson, Martin Schalling.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21030213     DOI： 10.1016/j.schres.2010.10.002

Source DB:  PubMed          Journal:  Schizophr Res        ISSN： 0920-9964            Impact factor:   4.939


× No keyword cloud information.
  11 in total

1.  Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes.

Authors:  Ikwunga Wonodi; O Colin Stine; Korrapati V Sathyasaikumar; Rosalinda C Roberts; Braxton D Mitchell; L Elliot Hong; Yasushi Kajii; Gunvant K Thaker; Robert Schwarcz
Journal:  Arch Gen Psychiatry       Date:  2011-07

2.  Importance of kynurenine 3-monooxygenase for spontaneous firing and pharmacological responses of midbrain dopamine neurons: Relevance for schizophrenia.

Authors:  Maximilian Tufvesson-Alm; Lilly Schwieler; Robert Schwarcz; Michel Goiny; Sophie Erhardt; Göran Engberg
Journal:  Neuropharmacology       Date:  2018-06-05       Impact factor: 5.250

3.  Elevated levels of kynurenic acid during gestation produce neurochemical, morphological, and cognitive deficits in adulthood: implications for schizophrenia.

Authors:  Michelle L Pershing; David M Bortz; Ana Pocivavsek; Peter J Fredericks; Christinna V Jørgensen; Sarah A Vunck; Benedetta Leuner; Robert Schwarcz; John P Bruno
Journal:  Neuropharmacology       Date:  2014-11-01       Impact factor: 5.250

4.  Kynurenine 3-monooxygenase polymorphisms: relevance for kynurenic acid synthesis in patients with schizophrenia and healthy controls.

Authors:  Maria Holtze; Peter Saetre; Göran Engberg; Lilly Schwieler; Thomas Werge; Ole A Andreassen; Håkan Hall; Lars Terenius; Ingrid Agartz; Erik G Jönsson; Martin Schalling; Sophie Erhardt
Journal:  J Psychiatry Neurosci       Date:  2012-01       Impact factor: 6.186

Review 5.  Kynurenines, Gender and Neuroinflammation; Showcase Schizophrenia.

Authors:  J de Bie; C K Lim; G J Guillemin
Journal:  Neurotox Res       Date:  2016-06-24       Impact factor: 3.911

6.  Continuous kynurenine administration during the prenatal period, but not during adolescence, causes learning and memory deficits in adult rats.

Authors:  Ana Pocivavsek; Marian A R Thomas; Greg I Elmer; John P Bruno; Robert Schwarcz
Journal:  Psychopharmacology (Berl)       Date:  2014-03-04       Impact factor: 4.530

7.  The Genetic Link between Parkinson's Disease and the Kynurenine Pathway Is Still Missing.

Authors:  Nóra Török; Rita Török; Zoltán Szolnoki; Ferenc Somogyvári; Péter Klivényi; László Vécsei
Journal:  Parkinsons Dis       Date:  2015-02-17

8.  Human umbilical cord-derived mesenchymal stem cells alleviate schizophrenia-relevant behaviors in amphetamine-sensitized mice by inhibiting neuroinflammation.

Authors:  Min-Jung You; Minji Bang; Hyun-Sun Park; Bohyun Yang; Kyu Beom Jang; Jongman Yoo; Dong-Youn Hwang; MinYoung Kim; Borah Kim; Sang-Hyuk Lee; Min-Soo Kwon
Journal:  Transl Psychiatry       Date:  2020-04-27       Impact factor: 6.222

Review 9.  Kynurenine 3-Monooxygenase: An Influential Mediator of Neuropathology.

Authors:  Jennifer M Parrott; Jason C O'Connor
Journal:  Front Psychiatry       Date:  2015-08-20       Impact factor: 4.157

Review 10.  Kynurenine-3-monooxygenase: A new direction for the treatment in different diseases.

Authors:  Yifei Lu; Mingmei Shao; Tao Wu
Journal:  Food Sci Nutr       Date:  2020-01-20       Impact factor: 2.863
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.